🟤Colorectal-anal cancer oral abstracts #ASCO25 ASCO 🟨LBA1-Plenary-Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC)

#ASCO25 NEJM BREAKWATER: Encorafenib + cetuximab + mFOLFOX6 vs standard care in 1L BRAF V600E mCRC PFS➡️12.8 vs 7.1 mo✅️ OS➡️ 30.3 vs 15.1 mo✅️👏 💥For one of the hardest-to-treat mCRC subtypes, this triplet shows substantial survival benefit. nejm.org/doi/full/10.10…

Original Article: Structured Exercise after Adjuvant Chemotherapy for Colon Cancer (CHALLENGE phase 3 trial) nej.md/4mh5RPL #ASCO25 | ASCO

#ASCO25 | Efficacia e sicurezza nella real world di avelumab in pazienti immunocompromessi con carcinoma a cellule di Merkel: un assaggio dell’intervista a Nicola Fazio, a breve sul Day 3 di OncoInfo! 🔜 IEO

A cell-free DNA blood test could be an option for patients who repeatedly decline colonoscopy or stool testing for #ColorectalCancer screening. #ASCO25 Read the new JAMA Original Investigation to learn more. ja.ma/3FC1wWU

How the gut microbiome could be useful as a biomarker for colon cancer screening nature.com/articles/s4159…

🚨Two consensus guidelines for appendiceal tumors with and without peritoneal involvement - ACS Journal Cancer 💥When trials fall short, consensus steps in 📄 Part 1: acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… 📄 Part 2: acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… 🔍 >90% agreement among 138 experts. #GItumors

Comprehensive genomic profiling by liquid biopsy in refractory mCRC pts who are candidate for anti-EGFR rechallenge therapy: findings from the CAVE-2 GOIM trial in ESMO Open. 41.7% had RAS/BRAF-V600 alterations, 55.5% others, 34.3% were ESCAT tier I. esmoopen.com/article/S2059-…

Scientists hide messages in papers to game AI peer review nature.com/articles/d4158…

Just published in European Journal of Cancer 📢 "Integrating Tissue and Liquid Biopsy Comprehensive Genomic Profiling to Predict Efficacy of anti-EGFR Therapies in Metastatic Colorectal Cancer: Findings From the CAPRI-2 GOIM Study " ejcancer.com/article/S0959-…

All’ESMO GC 2025 gli aggiornamenti del trial CAPRI -2: quali novità sulla biopsia liquida nel predire la risposta a cetuximab + FOLFIRI nella I linea del carcinoma colorettale metastatico RAS/BRAFV600E wild type? Lo abbiamo chiesto a Fortunato Ciardiello. oncoinfo.it/congressi/capr…

We honor the late Dr. Harmon Eyre, who served as American Cancer Society Chief Medical Officer and Editor-in-Chief of CA from 1993 to 2008. Read the full tribute by former ACS Chief Executive Officer John Seffrin and past Chief Medical Officer Otis Brawley. acsjournals.onlinelibrary.wiley.com/doi/full/10.33…

New ADC data published in Nature Medicine by Scott Kopetz & colleagues: Precemtabart tocentecan, an anti-CEACAM5 antibody–drug conjugate, in metastatic colorectal cancer: a phase 1 trial nature.com/articles/s4159… 90% of #ColorectalCancer cases over express cell surface CEACAM5

Excellent review in NatureRevClinOncol📣🌟 An integrated algorithm for Cancer of Unknown Primary diagnosis & treatment combines histologic morphology, IHC, gene expression profiling & genomic sequencing, establishing a new therapeutic paradigm. doi.org/10.1038/s41571… OncoAlert

The peer-review crisis: how to fix an overloaded system nature.com/articles/d4158…

🆕article in press: Risk of disease progression in the first-line therapy of metastatic colorectal cancer to guide disease re-assessments - analysis of eleven trials by AIO and GONO doi.org/10.1016/j.anno…

VERY proud of our MD Anderson Cancer Center team's work now online Cancer Cell for BRAF+EGFR+PD1 blockade in MSS, BRAF V600E mCRC. ORR 50%, mPFS >7 mos w/encorafenib + cetuximab + nivolumab 🧵to expand IO benefit+liquid biopsy utility in high-risk MSS CRC pts bit.ly/4g1upd5

Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

🧬Lynch syndrome & ICIs: risk of new cancers (2015–24, n=93) 🔗 doi.org/10.1016/j.esmo… ⚠️ 8% developed new dMMR/MSI-H tumors (urothelial, CRC, pancreas, skin) 🔎 39% had de novo colorectal polyps on follow-up ⏳ Long-term surveillance remains essential even after ICI response

🇮🇹 The ROME trial marks a milestone for Italy’s precision oncology platform: 6 years of dedication, 40 centers, 1,794 patients sequenced. A national effort to bring genomics to the heart of cancer care. ESMO - Eur. Oncology IEO Università degli Studi di Milano